Novo’s next-generation obesity drug shows 25% weight loss in women in late-stage analysis
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.
Novo said Tuesday that CagriSema, a semaglutide and cagrilintide injection expected early next year, averaged 25% weight loss at 68 weeks in a post-trial analysis of roughly 2,300 women with obesity or overweight versus 3% on placebo; in about 1,900 women by menopausal status, loss reached 26.7%, 24.8%, and 23.1%, and Novo said further work is needed to confirm the analyses.
Continue in the app — vote & join in ➔Source: CNBC Top News · via ahirlevel.hu